Eshan U Patel1, Andrea L Cox2, Shruti H Mehta3, Denali Boon3, Caroline E Mullis4, Jacquie Astemborski3, William O Osburn2, Jeffrey Quinn2, Andrew D Redd5, Gregory D Kirk6, David L Thomas6, Thomas C Quinn7, Oliver Laeyendecker7. 1. Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. Department of Medicine, Johns Hopkins University School of Medicine. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Medicine, New York Medical College, New York. 5. Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health Department of Medicine, Johns Hopkins University School of Medicine. 6. Department of Medicine, Johns Hopkins University School of Medicine Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 7. Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health Department of Medicine, Johns Hopkins University School of Medicine Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
BACKGROUND: Sensitive methods are needed to estimate the population-level incidence of hepatitis C virus (HCV) infection. METHODS: We developed an HCV immunoglobulin G (IgG) antibody avidity assay by modifying the Ortho 3.0 HCV enzyme-linked immunoassay and tested 997 serum or plasma samples from 568 people who inject drugs enrolled in prospective cohort studies. Avidity-based testing algorithms were evaluated by their (1) mean duration of recent infection (MDRI), defined as the average time an individual is identified as having been recently infected, according to a given algorithm; (2) false-recent rate, defined as the proportion of samples collected >2 years after HCV seroconversion that were misclassified as recent; (3) sample sizes needed to estimate incidence; and (4) power to detect a reduction in incidence between serial cross-sectional surveys. RESULTS: A multiassay algorithm (defined as an avidity index of <30%, followed by HCV viremia detection) had an MDRI of 147 days (95% confidence interval [CI], 125-195 days), and the false-recent rates were 0.7% (95% CI, .2%-1.8%) and 7.6% (95% CI, 4.2%-12.3%) among human immunodeficiency virus (HIV)-negative and HIV-positive persons, respectively. In various simulated high-risk populations, this algorithm required <1000 individuals to estimate incidence (relative standard error, 30%) and had >80% power to detect a 50% reduction in incidence. CONCLUSIONS: Avidity-based algorithms have the capacity to accurately estimate HCV infection incidence and rapidly assess the impact of public health efforts among high-risk populations. Efforts to optimize this method should be prioritized. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Sensitive methods are needed to estimate the population-level incidence of hepatitis C virus (HCV) infection. METHODS: We developed an HCV immunoglobulin G (IgG) antibody avidity assay by modifying the Ortho 3.0 HCV enzyme-linked immunoassay and tested 997 serum or plasma samples from 568 people who inject drugs enrolled in prospective cohort studies. Avidity-based testing algorithms were evaluated by their (1) mean duration of recent infection (MDRI), defined as the average time an individual is identified as having been recently infected, according to a given algorithm; (2) false-recent rate, defined as the proportion of samples collected >2 years after HCV seroconversion that were misclassified as recent; (3) sample sizes needed to estimate incidence; and (4) power to detect a reduction in incidence between serial cross-sectional surveys. RESULTS: A multiassay algorithm (defined as an avidity index of <30%, followed by HCV viremia detection) had an MDRI of 147 days (95% confidence interval [CI], 125-195 days), and the false-recent rates were 0.7% (95% CI, .2%-1.8%) and 7.6% (95% CI, 4.2%-12.3%) among human immunodeficiency virus (HIV)-negative and HIV-positive persons, respectively. In various simulated high-risk populations, this algorithm required <1000 individuals to estimate incidence (relative standard error, 30%) and had >80% power to detect a 50% reduction in incidence. CONCLUSIONS: Avidity-based algorithms have the capacity to accurately estimate HCV infection incidence and rapidly assess the impact of public health efforts among high-risk populations. Efforts to optimize this method should be prioritized. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
HCV; HIV; antibody response; incidence testing; people who inject drugs; recent infection; surveillance
Authors: Sunil Suhas Solomon; Shruti H Mehta; Aylur K Srikrishnan; Suniti Solomon; Allison M McFall; Oliver Laeyendecker; David D Celentano; Syed H Iqbal; Santhanam Anand; Canjeevaram K Vasudevan; Shanmugam Saravanan; Gregory M Lucas; Muniratnam S Kumar; Mark S Sulkowski; Thomas C Quinn Journal: Lancet Infect Dis Date: 2014-12-03 Impact factor: 25.071
Authors: Shauna Onofrey; Jasneet Aneja; Gillian A Haney; Ellen H Nagami; Alfred DeMaria; Georg M Lauer; Kelsey Hills-Evans; Kerri Barton; Stephanie Kulaga; Melinda J Bowen; Noelle Cocoros; Barbara H McGovern; Daniel R Church; Arthur Y Kim Journal: Ann Intern Med Date: 2015-08-18 Impact factor: 25.391
Authors: S Klimashevskaya; A Obriadina; T Ulanova; G Bochkova; A Burkov; A Araujo; Susan L Stramer; Leslie H Tobler; Michael P Busch; Howard A Fields Journal: J Clin Microbiol Date: 2007-08-22 Impact factor: 5.948
Authors: Dale M Netski; Tim Mosbruger; Erik Depla; Geert Maertens; Stuart C Ray; Robert G Hamilton; Stacy Roundtree; David L Thomas; Jane McKeating; Andrea Cox Journal: Clin Infect Dis Date: 2005-07-22 Impact factor: 9.079
Authors: Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï Journal: PLoS One Date: 2014-07-28 Impact factor: 3.240
Authors: L Leon; S Kasereka; F Barin; C Larsen; L Weill-Barillet; X Pascal; S Chevaliez; J Pillonel; M Jauffret-Roustide; Y LE Strat Journal: Epidemiol Infect Date: 2016-12-22 Impact factor: 4.434
Authors: Hong-Van Tieu; Oliver Laeyendecker; Vijay Nandi; Rebecca Rose; Reinaldo Fernandez; Briana Lynch; Donald R Hoover; Victoria Frye; Beryl A Koblin Journal: PLoS One Date: 2018-07-18 Impact factor: 3.240
Authors: Denali Boon; Veronica Bruce; Eshan U Patel; Jeffrey Quinn; Aylur K Srikrishnan; Saravanan Shanmugam; Syed Iqbal; Pachamuthu Balakrishnan; Matthew Sievers; Gregory D Kirk; David L Thomas; Thomas C Quinn; Andrea L Cox; Kimberly A Page; Sunil S Solomon; Shruti H Mehta; Oliver Laeyendecker Journal: J Hepatol Date: 2020-03-30 Impact factor: 30.083